<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plospath</journal-id><journal-title-group>
<journal-title>PLoS Pathogens</journal-title></journal-title-group>
<issn pub-type="ppub">1553-7366</issn>
<issn pub-type="epub">1553-7374</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PPATHOGENS-D-13-02990</article-id>
<article-id pub-id-type="doi">10.1371/journal.ppat.1003983</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Opinion</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject><subj-group><subject>Bacterial diseases</subject><subj-group><subject>Mycoplasma pneumonia</subject></subj-group></subj-group><subj-group><subject>Infectious diseases of the nervous system</subject><subj-group><subject>Encephalitis</subject><subject>Postinfectious encephalitis</subject></subj-group></subj-group></subj-group><subj-group><subject>Neurology</subject></subj-group><subj-group><subject>Pediatrics</subject></subj-group></subj-group></article-categories>
<title-group>
<article-title>Antibody Responses to <italic>Mycoplasma pneumoniae</italic>: Role in Pathogenesis and Diagnosis of Encephalitis?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Meyer Sauteur</surname><given-names>Patrick M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jacobs</surname><given-names>Bart C.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Spuesens</surname><given-names>Emiel B. M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jacobs</surname><given-names>Enno</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nadal</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Vink</surname><given-names>Cornelis</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>van Rossum</surname><given-names>Annemarie M. C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Erasmus MC–Sophia Children's Hospital, University Medical Center, Rotterdam, The Netherlands</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Laboratory of Pediatrics, Erasmus MC–Sophia Children's Hospital, University Medical Center, Rotterdam, The Netherlands</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital of Zurich, Zurich, Switzerland</addr-line></aff>
<aff id="aff4"><label>4</label><addr-line>Children's Research Center (CRC), University Children's Hospital of Zurich, Zurich, Switzerland</addr-line></aff>
<aff id="aff5"><label>5</label><addr-line>Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands</addr-line></aff>
<aff id="aff6"><label>6</label><addr-line>Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands</addr-line></aff>
<aff id="aff7"><label>7</label><addr-line>TU Dresden, Medical Faculty Carl Gustav Carus, Institute of Medical Microbiology and Hygiene, Dresden, Germany</addr-line></aff>
<aff id="aff8"><label>8</label><addr-line>Erasmus University College, Erasmus University, Rotterdam, The Netherlands</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Haldar</surname><given-names>Kasturi</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Notre Dame, United States of America</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">p.meyersauteur@erasmusmc.nl</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
</author-notes>
<pub-date pub-type="collection"><month>6</month><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>12</day><month>6</month><year>2014</year></pub-date>
<volume>10</volume>
<issue>6</issue>
<elocation-id>e1003983</elocation-id><permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Meyer Sauteur et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><funding-group><funding-statement>PMMS is supported by a Swiss National Science Foundation (SNSF) grant (PBZHP3_147290). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="5"/></counts></article-meta>
</front>
<body><sec id="s1">
<title/>
<p>The pathogenesis of encephalitis associated with the respiratory pathogen <italic>Mycoplasma pneumoniae</italic> is not well understood. A direct infection of the central nervous system (CNS) and an immune-mediated process have been discussed <xref ref-type="bibr" rid="ppat.1003983-Narita1">[1]</xref>. Recent observations suggest that intrathecally detectable antibodies against the bacterium, which can serve to establish the etiology of encephalitis, may indeed mediate the disease. </p>
<p> <italic>Mycoplasma pneumoniae</italic> is a major cause of upper and lower respiratory tract infections in humans worldwide, particularly in children <xref ref-type="bibr" rid="ppat.1003983-Foy1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Lind1">[3]</xref>. Up to 40% of community-acquired pneumonia in children admitted to the hospital are attributed to <italic>M. pneumoniae</italic> infection <xref ref-type="bibr" rid="ppat.1003983-Michelow1">[4]</xref>–<xref ref-type="bibr" rid="ppat.1003983-Juven1">[7]</xref>. Although the infection is rarely fatal, patients of every age can develop severe and fulminant disease. Apart from the respiratory tract infection, <italic>M. pneumoniae</italic> can cause extrapulmonary manifestations. They occur in up to 25% of manifest <italic>M. pneumoniae</italic> infections and may affect almost every organ, including the skin as well as the hematologic, cardiovascular, musculoskeletal, and nervous system <xref ref-type="bibr" rid="ppat.1003983-Narita2">[8]</xref>. Encephalitis is one of the most common and severe complications <xref ref-type="bibr" rid="ppat.1003983-Narita1">[1]</xref>. <italic>M. pneumoniae</italic> infection is established in 5%–10% of pediatric encephalitis patients <xref ref-type="bibr" rid="ppat.1003983-Christie1">[9]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Bitnun1">[10]</xref>, and up to 60% of them show neurologic sequelae <xref ref-type="bibr" rid="ppat.1003983-Bitnun1">[10]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Bitnun2">[11]</xref>.</p>
<p>It is important to establish the cause of encephalitis at an early stage in order to specifically treat what can be treated and to avoid unnecessary treatment. The diagnosis of <italic>M. pneumoniae</italic> encephalitis is challenging. The current diagnostic algorithm of the “Consensus Statement of the International Encephalitis Consortium” <xref ref-type="bibr" rid="ppat.1003983-Venkatesan1">[12]</xref> recommends for the diagnosis of <italic>M. pneumoniae</italic> infection in children with encephalitis (1) serology and polymerase chain reaction (PCR) from throat samples (routine studies), and if positive test results and/or respiratory symptoms are present, then (2) additionally PCR in cerebrospinal fluid (CSF) (conditional studies).</p>
<p>However, <italic>M. pneumoniae</italic> serology and PCR in the respiratory tract cannot discern between colonization and infection in a clinically relevant time frame <xref ref-type="bibr" rid="ppat.1003983-Spuesens1">[13]</xref>. The main reason for this is the relatively high prevalence of <italic>M. pneumoniae</italic> in the upper respiratory tract of healthy children (up to 56%) <xref ref-type="bibr" rid="ppat.1003983-Spuesens1">[13]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Wood1">[14]</xref>. The demonstrated positive serological results in such asymptomatic PCR-positive children (positive immunoglobulin (Ig) M in 17%, IgG in 24%, and IgA in 6% of 66 cases) <xref ref-type="bibr" rid="ppat.1003983-Spuesens1">[13]</xref> may simply reflect one or more previous encounters with <italic>M. pneumoniae</italic> and are not necessarily related to the presence of <italic>M. pneumoniae</italic> in the respiratory tract. It is clear that this may give rise to an overestimation of the <italic>M. pneumoniae</italic>-related disease burden. A more reliable diagnosis of <italic>M. pneumoniae</italic> infection may be achieved by using paired patient sera in order to detect seroconversion and/or a 4-fold increase in antibody titers in addition to PCR (<xref ref-type="table" rid="ppat-1003983-t001">Table 1</xref>; table references: <xref ref-type="bibr" rid="ppat.1003983-Spuesens1">[13]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Jacobs1">[15]</xref>–<xref ref-type="bibr" rid="ppat.1003983-Dumke1">[24]</xref>). However, such procedures are time-consuming and are therefore neither practicable nor useful in an acutely ill patient.</p>
<table-wrap id="ppat-1003983-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1003983.t001</object-id><label>Table 1</label><caption>
<title>Overview of diagnostic tests for <italic>M. pneumoniae</italic>.</title>
</caption><alternatives><graphic id="ppat-1003983-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003983.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Method</td>
<td align="left" rowspan="1" colspan="1">Test</td>
<td align="left" rowspan="1" colspan="1">Target/Antigen</td>
<td align="left" rowspan="1" colspan="1">Antibodies</td>
<td align="left" rowspan="1" colspan="1">Specimen</td>
<td align="left" rowspan="1" colspan="1">Performance<xref ref-type="table-fn" rid="nt102">1</xref></td>
<td align="left" rowspan="1" colspan="1">Value</td>
<td align="left" rowspan="1" colspan="1">Comments</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Direct identification of <italic>M. pneumoniae</italic></td>
<td align="left" rowspan="1" colspan="1">PCR</td>
<td align="left" rowspan="1" colspan="1">Different target genes (e.g., P1 gene, 16S rDNA, 16S rRNA, RepMP elements, etc.)</td>
<td align="left" rowspan="1" colspan="1">-</td>
<td align="left" rowspan="1" colspan="1">Respiratory specimen (nasopharyngeal secretion, pharyngeal swab, sputum, bronchoalveolar lavage), CSF, and other bodily fluids or tissues</td>
<td align="left" rowspan="1" colspan="1">High sensitivity, high specificity</td>
<td align="left" rowspan="1" colspan="1">RD<xref ref-type="table-fn" rid="nt103">2</xref></td>
<td align="left" rowspan="1" colspan="1">NAATs provide fast results (in less than a day) and may be earlier than serology (because antibody production requires several days); validation and standardization required for routine diagnostic</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Culture</td>
<td align="left" rowspan="1" colspan="1">-</td>
<td align="left" rowspan="1" colspan="1">-</td>
<td align="left" rowspan="1" colspan="1">Respiratory specimen (see above)</td>
<td align="left" rowspan="1" colspan="1">Low sensitivity, high specificity</td>
<td align="left" rowspan="1" colspan="1">AD</td>
<td align="left" rowspan="1" colspan="1">Special enriched broth or agar media; isolation takes up to 21 days</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Nonspecific serological tests for <italic>M. pneumoniae</italic></td>
<td align="left" rowspan="1" colspan="1">Cold-agglutinin test (“bedside test”)</td>
<td align="left" rowspan="1" colspan="1">Erythrocytes (I antigen)</td>
<td align="left" rowspan="1" colspan="1">Cold agglutinins (IgM)</td>
<td align="left" rowspan="1" colspan="1">Serum</td>
<td align="left" rowspan="1" colspan="1">Low sensitivity, low specificity</td>
<td align="left" rowspan="1" colspan="1">-<xref ref-type="table-fn" rid="nt104">3</xref></td>
<td align="left" rowspan="1" colspan="1">Cold agglutinins target the I antigen of erythrocytes (alternative theory: cold agglutinins target directly <italic>M. pneumoniae</italic> adhered to erythrocytes); positive in only about 50% and in the first week of symptoms; less well studied in children; cross-reactivity with other pathogens and noninfectious diseases</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Specific serological tests for <italic>M. pneumoniae</italic></td>
<td align="left" rowspan="1" colspan="1">CFT</td>
<td align="left" rowspan="1" colspan="1">Crude antigen extract with glycolipids and/or proteins</td>
<td align="left" rowspan="1" colspan="1">Igs (no discrimination between isotypes)</td>
<td align="left" rowspan="1" colspan="1">Serum</td>
<td align="left" rowspan="1" colspan="1">Sensitivity and specificity comparable to EIA</td>
<td align="left" rowspan="1" colspan="1">-<xref ref-type="table-fn" rid="nt104">3</xref></td>
<td align="left" rowspan="1" colspan="1">Positive criteria: 4-fold titer increase between acute and convalescent sera or single titer ≥1∶32; cross-reactivity with other pathogens and noninfectious diseases</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">PA</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">IgM and IgG simultaneously</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">-<xref ref-type="table-fn" rid="nt104">3</xref></td>
<td align="left" rowspan="1" colspan="1">See above</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">EIA</td>
<td align="left" rowspan="1" colspan="1">Proteins (e.g., adhesion protein P1) and/or glycolipids</td>
<td align="left" rowspan="1" colspan="1">IgM, IgG,<xref ref-type="table-fn" rid="nt105">4</xref><sup>,</sup><xref ref-type="table-fn" rid="nt106">5</xref> (IgA)<xref ref-type="table-fn" rid="nt107">6</xref></td>
<td align="left" rowspan="1" colspan="1">Serum<xref ref-type="table-fn" rid="nt105">4</xref>, CSF<xref ref-type="table-fn" rid="nt106">5</xref><sup>,</sup><xref ref-type="table-fn" rid="nt108">7</xref>, other bodily fluids<xref ref-type="table-fn" rid="nt108">7</xref></td>
<td align="left" rowspan="1" colspan="1">Moderate-high sensitivity, moderate-high specificity</td>
<td align="left" rowspan="1" colspan="1">RD</td>
<td align="left" rowspan="1" colspan="1">The sensitivity depends on the time point of the first serum and on the availability of paired sera (for seroconversion and/or rise in titer); “gold standard”: 4-fold titer increase as measured in paired sera</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Immunoblotting</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">High sensitivity, high specificity<xref ref-type="table-fn" rid="nt109">8</xref></td>
<td align="left" rowspan="1" colspan="1">AD</td>
<td align="left" rowspan="1" colspan="1">Confirmatory assay</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">IFA</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Less sensitive and less specific than EIA</td>
<td align="left" rowspan="1" colspan="1">AD</td>
<td align="left" rowspan="1" colspan="1">Subjective interpretation</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>Abbreviations: AD, advanced diagnostic test; CFT, complement fixation test; CNS, central nervous system; CSF, cerebrospinal fluid; EIA, enzyme immunoassay; IFA, immunofluorescent assay; Ig, immunoglobulin; NAATs, nucleic acid amplification tests; PA, particle agglutination assay; PCR, polymerase chain reaction; RD, routine diagnostic test; RepMP, repeated <italic>M. pneumoniae</italic> DNA. References: <xref ref-type="bibr" rid="ppat.1003983-Spuesens1">[13]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Jacobs1">[15]</xref>–<xref ref-type="bibr" rid="ppat.1003983-Dumke1">[24]</xref>.</p></fn><fn id="nt102"><label>1</label><p>Qualitative statements included because of the wide range of test performances, which depend on the assay, the patient cohort (children and/or adults), the reference standard (PCR, culture, and/or serology), the respiratory specimen (for PCR), and the time point of the sample collection after disease onset (for EIA)—e.g., sensitivities and specificities for PCR <xref ref-type="bibr" rid="ppat.1003983-Loens1">[17]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Nadal1">[18]</xref>: 79%–100% and 96%–99%; IgM EIA (in relation to PCR) <xref ref-type="bibr" rid="ppat.1003983-Beersma1">[19]</xref>: 35%–77% and 49%–100%; and for IgG EIA <xref ref-type="bibr" rid="ppat.1003983-Loens1">[17]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Beersma1">[19]</xref>: 37%–100% (no indication on specificity because of missing information on previous <italic>M. pneumoniae</italic> infections).</p></fn><fn id="nt103"><label>2</label><p>Epidemiological differentiation of clinical strains on the basis of differences in the P1 gene by PCR or in the number of repetitive sequences at a given genomic locus by multilocus variable-number tandem-repeat analysis (MLVA) <xref ref-type="bibr" rid="ppat.1003983-Jacobs2">[23]</xref>.</p></fn><fn id="nt104"><label>3</label><p>Largely replaced by EIA.</p></fn><fn id="nt105"><label>4</label><p><bold>Kinetics of antibody responses in blood.</bold> <underline>IgM</underline>: onset: within 1 week after the onset of symptoms; peak: 3–6 weeks; persistence: months (to years). <underline>IgG</underline>: onset and peak: 2 weeks after IgM; persistence: years (to lifelong); reinfection in adults may lead directly to an IgG response in the absence of an IgM response. <underline>IgA</underline>: onset, peak, and decrease earlier than IgM.</p></fn><fn id="nt106"><label>5</label><p><bold>Antibody responses in the CNS differ from blood.</bold> There is no switch from an IgM to an IgG response, the pattern of IgM, IgG, and IgA synthesis remains rather constant and depends on the cause, and there is a long-lasting and slow decay of intrathecal antibody synthesis <xref ref-type="bibr" rid="ppat.1003983-Reiber1">[22]</xref>. In <italic>M. pneumoniae</italic> encephalitis, a dominant IgM response has been observed <xref ref-type="bibr" rid="ppat.1003983-MeyerSauteur1">[29]</xref>.</p></fn><fn id="nt107"><label>6</label><p>The prevalence of serum IgA determined by EIA has been shown to be very low in PCR-positive children with symptomatic respiratory tract infection (2.0%) <xref ref-type="bibr" rid="ppat.1003983-Spuesens1">[13]</xref>.</p></fn><fn id="nt108"><label>7</label><p>To our knowledge, no validated test is available.</p></fn><fn id="nt109"><label>8</label><p>Immunoblotting with a combination of at least five specific <italic>M. pneumoniae</italic> proteins showed sensitivities (in relation to PCR) of 83% (IgM), 51% (IgG), and 64% (IgA), and specificities of 94%–100% (IgM), 98%–100% (IgG), and 93%–97% (IgA) <xref ref-type="bibr" rid="ppat.1003983-Dumke1">[24]</xref>.</p></fn></table-wrap-foot></table-wrap>
<p>The detection rate of <italic>M. pneumoniae</italic> by PCR in the CSF of <italic>M. pneumoniae</italic> encephalitis patients is relatively low (0%–14%) <xref ref-type="bibr" rid="ppat.1003983-Christie1">[9]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Bitnun1">[10]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Daxboeck1">[25]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Domenech1">[26]</xref>. Moreover, various cases with <italic>M. pneumoniae</italic> encephalitis in which bacterial DNA could not be detected in the CSF had a more prolonged duration of respiratory symptoms before the onset of encephalitis (&gt;5–7 days) <xref ref-type="bibr" rid="ppat.1003983-Bitnun1">[10]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Daxboeck1">[25]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Narita3">[27]</xref>. These cases indicate that <italic>M. pneumoniae</italic> encephalitis may exemplify a postinfectious phenomenon that manifests after clearance of the bacteria from the CNS or respiratory tract by the immune system. The immune response to <italic>M. pneumoniae</italic> in the CNS or other sites may also contribute to the encephalitis (<xref ref-type="fig" rid="ppat-1003983-g001">Figure 1</xref>; figure references: <xref ref-type="bibr" rid="ppat.1003983-Narita1">[1]</xref>).</p>
<fig id="ppat-1003983-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1003983.g001</object-id><label>Figure 1</label><caption>
<title>Proposed schematic pathomechanisms in <italic>M. pneumoniae</italic> encephalitis.</title>
<p>(Left) Respiratory tract infection. <italic>M. pneumoniae</italic> resides mostly extracellularly on epithelial surfaces. Its close association allows the production of direct injury by a variety of local cytotoxic effects. Furthermore, it can induce inflammatory responses, elicited by both adhesion proteins and glycolipid epitopes that result in pneumonia. (Right) Encephalitis. Extrapulmonary disease of the CNS is characterized by systemic dissemination with resultant direct infection and local tissue injury (A) or immune-mediated injury (B,C). The latter may occur as a result of cross-reactive antibodies against myelin components, e.g., gangliosides and galactocerebroside C. These antibodies could theoretically have originated from intrathecal synthesis (B) or from outside the CNS (C). Figure adapted from <xref ref-type="bibr" rid="ppat.1003983-Narita1">[1]</xref>; see references in the text.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003983.g001" position="float" xlink:type="simple"/></fig>
<p>Interestingly, a promising diagnostic marker for <italic>M. pneumoniae</italic> encephalitis has recently emerged from a few case studies. In one study, intrathecal synthesis of antibodies to <italic>M. pneumoniae</italic> was reported in 14 cases of <italic>M. pneumoniae</italic> encephalitis (74%) <xref ref-type="bibr" rid="ppat.1003983-Bencina1">[28]</xref>. The intrathecal production of antibodies is generally considered a highly specific marker for infection of the CNS <xref ref-type="bibr" rid="ppat.1003983-Reiber1">[22]</xref>. All cases that underwent PCR testing (93%) indeed had a positive PCR targeting <italic>M. pneumoniae</italic> in the CSF <xref ref-type="bibr" rid="ppat.1003983-Bencina1">[28]</xref> even though it has been recently demonstrated that intrathecal antibody responses to <italic>M. pneumoniae</italic> but not bacterial DNA can be present at the onset of clinical encephalitis <xref ref-type="bibr" rid="ppat.1003983-MeyerSauteur1">[29]</xref>. In another study, it was reported that intrathecal antibodies to <italic>M. pneumoniae</italic> were found to cross-react with galactocerebroside C (GalC) in eight out of 21 (38%) of <italic>M. pneumoniae</italic> encephalitis cases <xref ref-type="bibr" rid="ppat.1003983-Christie2">[30]</xref>. All eight cases showed a negative PCR targeting <italic>M. pneumoniae</italic> in CSF. The cross-reactivity in these cases is likely induced by molecular mimicry between bacterial glycolipids and host myelin glycolipids, including GalC and gangliosides (<xref ref-type="fig" rid="ppat-1003983-g002">Figure 2</xref>; figure references: <xref ref-type="bibr" rid="ppat.1003983-Jacobs3">[31]</xref>–<xref ref-type="bibr" rid="ppat.1003983-Willison1">[34]</xref>). Cross-reactive, anti-GalC antibodies have previously been detected in patients with Guillain-Barré syndrome (GBS) who suffered from a preceding <italic>M. pneumoniae</italic> infection <xref ref-type="bibr" rid="ppat.1003983-Kusunoki1">[32]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Ang1">[35]</xref>–<xref ref-type="bibr" rid="ppat.1003983-Samukawa1">[38]</xref>. GBS is a typical postinfectious immune-mediated peripheral neuropathy <xref ref-type="bibr" rid="ppat.1003983-vanDoorn1">[39]</xref>. In GBS, cross-reactive antibodies cause complement activation and formation of a membrane attack complex at the peripheral nerves, resulting in neuromuscular paralysis. Anti-GalC antibodies have been associated with demyelination in patients with GBS <xref ref-type="bibr" rid="ppat.1003983-Ang1">[35]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Samukawa1">[38]</xref>. Moreover, these anti-GalC antibodies cause neuropathy in rabbits that are immunized with GalC <xref ref-type="bibr" rid="ppat.1003983-Saida1">[40]</xref>. Such antibodies may also be involved in demyelination of central nerve cells in <italic>M. pneumoniae</italic> encephalitis, as a significant correlation was found between the presence of anti-GalC antibodies in the CSF and demyelination (<italic>p</italic> = 0.026) <xref ref-type="bibr" rid="ppat.1003983-Christie2">[30]</xref>.</p>
<fig id="ppat-1003983-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.ppat.1003983.g002</object-id><label>Figure 2</label><caption>
<title>Schematic structures responsible for molecular mimicry between <italic>M. pneumoniae</italic> and neuronal cells.</title>
<p>(Left) <italic>M. pneumoniae</italic> adhesion proteins and glycolipids. The immunogenic and major cytadherence proteins P1 and P30 are densely clustered at the tip structure. The P1 protein <xref ref-type="bibr" rid="ppat.1003983-Jacobs3">[31]</xref> and glycolipids, e.g., those forming a GalC-like structure <xref ref-type="bibr" rid="ppat.1003983-Kusunoki1">[32]</xref>, elicit cross-reactive antibodies induced by molecular mimicry. (Right) Host myelin glycolipids, to which antibodies were found in patients with <italic>M. pneumoniae</italic> encephalitis. Glycolipids are organized in specialized functional microdomains called “lipid rafts” and play a part in the maintenance of the cell membrane structure. Abbreviations: GalC, galactocerebroside C; GQ1b, ganglioside quadrosialo 1b; GM1, ganglioside monosialo 1 (the numbers stand for the order of migration on thin-layer chromatography, and the lower-case letters stand for variations within basic structures); HMW, high-molecular-weight. Structures of <italic>M. pneumoniae</italic> adhesion proteins and host glycolipids are adapted from <xref ref-type="bibr" rid="ppat.1003983-Rottem1">[33]</xref> and <xref ref-type="bibr" rid="ppat.1003983-Willison1">[34]</xref>, respectively.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003983.g002" position="float" xlink:type="simple"/></fig>
<p>Anti-GalC antibodies have not only been detected in CSF but also in the serum of <italic>M. pneumoniae</italic> encephalitis patients <xref ref-type="bibr" rid="ppat.1003983-Christie2">[30]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Susuki1">[36]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Nishimura1">[41]</xref>–<xref ref-type="bibr" rid="ppat.1003983-Sugeno1">[43]</xref>, including rates from 13% (2/15) <xref ref-type="bibr" rid="ppat.1003983-Christie2">[30]</xref> to 100% (3/3) <xref ref-type="bibr" rid="ppat.1003983-Nishimura1">[41]</xref>, respectively. It is possible that during inflammation the blood-brain barrier (BBB) can become permeable, which would thereby enable antibodies to cross the BBB and cause disease. As a consequence, the cross-reactive antibodies in the CSF of <italic>M. pneumoniae</italic> encephalitis patients do not necessarily have to be produced intrathecally (<xref ref-type="fig" rid="ppat-1003983-g001">Figure 1</xref>).</p>
<p><italic>M. pneumoniae</italic> infections may also be followed by the production of antibodies to gangliosides, both in patients with GBS and in those with encephalitis. In <italic>M. pneumoniae</italic> encephalitis, such antibodies were directed against GQ1b <xref ref-type="bibr" rid="ppat.1003983-Kikuchi1">[44]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Steer1">[45]</xref> or GM1 <xref ref-type="bibr" rid="ppat.1003983-Fusco1">[46]</xref> (<xref ref-type="fig" rid="ppat-1003983-g002">Figure 2</xref>). Interestingly, anti-GQ1b antibodies are associated with a distinct and severe encephalitis variant, referred to as Bickerstaff brain stem encephalitis <xref ref-type="bibr" rid="ppat.1003983-Odaka1">[47]</xref>.</p>
<p>In conclusion, while PCR and serology may be of limited value in the diagnosis of <italic>M. pneumoniae</italic> encephalitis, the detection of intrathecal antibodies to <italic>M. pneumoniae</italic>, including cross-reactive antibodies against GalC and gangliosides, may be regarded as a promising new diagnostic tool.</p>
<p>The routine diagnostic workup of <italic>M. pneumoniae</italic> encephalitis should therefore aim for the detection of <italic>M. pneumoniae</italic> antibodies in both CSF and serum, in addition to <italic>M. pneumoniae</italic> PCR in CSF. Intrathecal antibodies can be detected by widely accessible enzyme immunoassays (EIAs) or immunoblotting (<xref ref-type="table" rid="ppat-1003983-t001">Table 1</xref>), while intrathecal antibody synthesis can be established either by calculation of an antibody index <xref ref-type="bibr" rid="ppat.1003983-Reiber1">[22]</xref> or through parallel immunoblotting of simultaneously collected CSF and serum samples <xref ref-type="bibr" rid="ppat.1003983-Monteyne1">[48]</xref>, <xref ref-type="bibr" rid="ppat.1003983-Granerod1">[49]</xref>. Antiganglioside antibodies can be detected routinely by some specialized laboratories, but their detection together with cross-reactive antibodies against GalC primarily serve scientific purposes and may help to clarify <italic>M. pneumoniae</italic> antibodies' immune target(s). Furthermore, their hypothesized role in the pathogenesis might provide a basis for immunomodulatory treatment in <italic>M. pneumoniae</italic> encephalitis.</p>
</sec></body>
<back><ref-list>
<title>References</title>
<ref id="ppat.1003983-Narita1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Narita</surname><given-names>M</given-names></name> (<year>2009</year>) <article-title>Pathogenesis of neurologic manifestations of <italic>Mycoplasma pneumoniae</italic> infection</article-title>. <source>Pediatr Neurol</source> <volume>41</volume>: <fpage>159</fpage>–<lpage>166</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Foy1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Foy</surname><given-names>HM</given-names></name> (<year>1993</year>) <article-title>Infections caused by <italic>Mycoplasma pneumoniae</italic> and possible carrier state in different populations of patients</article-title>. <source>Clin Infect Dis</source> <volume>17</volume> <supplement>Suppl 1</supplement><fpage>S37</fpage>–<lpage>S46</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Lind1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lind</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Benzon</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Clyde</surname><given-names>WA</given-names><suffix>Jr</suffix></name> (<year>1997</year>) <article-title>A seroepidemiological study of <italic>Mycoplasma pneumoniae</italic> infections in Denmark over the 50-year period 1946–1995</article-title>. <source>Eur J Epidemiol</source> <volume>13</volume>: <fpage>581</fpage>–<lpage>586</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Michelow1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Michelow</surname><given-names>IC</given-names></name>, <name name-style="western"><surname>Olsen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lozano</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rollins</surname><given-names>NK</given-names></name>, <name name-style="western"><surname>Duffy</surname><given-names>LB</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children</article-title>. <source>Pediatrics</source> <volume>113</volume>: <fpage>701</fpage>–<lpage>707</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Baer1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Engelcke</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Abele-Horn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schaad</surname><given-names>UB</given-names></name>, <name name-style="western"><surname>Heininger</surname><given-names>U</given-names></name> (<year>2003</year>) <article-title>Role of <italic>Chlamydia pneumoniae</italic> and <italic>Mycoplasma pneumoniae</italic> as causative agents of community-acquired pneumonia in hospitalised children and adolescents</article-title>. <source>Eur J Clin Microbiol Infect Dis</source> <volume>22</volume>: <fpage>742</fpage>–<lpage>745</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Principi1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Principi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Esposito</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Blasi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Allegra</surname><given-names>L</given-names></name> (<year>2001</year>) <collab xlink:type="simple">Mowgli study group</collab> (<year>2001</year>) <article-title>Role of <italic>Mycoplasma pneumoniae</italic> and <italic>Chlamydia pneumoniae</italic> in children with community-acquired lower respiratory tract infections</article-title>. <source>Clin Infect Dis</source> <volume>32</volume>: <fpage>1281</fpage>–<lpage>1289</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Juven1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Juven</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mertsola</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Waris</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Leinonen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Meurman</surname><given-names>O</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Etiology of community-acquired pneumonia in 254 hospitalized children</article-title>. <source>Pediatr Infect Dis J</source> <volume>19</volume>: <fpage>293</fpage>–<lpage>298</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Narita2"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Narita</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Pathogenesis of extrapulmonary manifestations of <italic>Mycoplasma pneumoniae</italic> infection with special reference to pneumonia</article-title>. <source>J Infect Chemother</source> <volume>16</volume>: <fpage>162</fpage>–<lpage>169</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Christie1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Christie</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Honarmand</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Talkington</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Gavali</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Preas</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Pediatric encephalitis: what is the role of <italic>Mycoplasma pneumoniae</italic>?</article-title> <source>Pediatrics</source> <volume>120</volume>: <fpage>305</fpage>–<lpage>313</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Bitnun1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bitnun</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ford-Jones</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Petric</surname><given-names>M</given-names></name>, <name name-style="western"><surname>MacGregor</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Heurter</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Acute childhood encephalitis and <italic>Mycoplasma pneumoniae</italic></article-title>. <source>Clin Infect Dis</source> <volume>32</volume>: <fpage>1674</fpage>–<lpage>1684</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Bitnun2"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bitnun</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ford-Jones</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Blaser</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>S</given-names></name> (<year>2003</year>) <article-title><italic>Mycoplasma pneumoniae</italic> encephalitis</article-title>. <source>Semin Pediatr Infect Dis</source> <volume>14</volume>: <fpage>96</fpage>–<lpage>107</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Venkatesan1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Venkatesan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tunkel</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Bloch</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Lauring</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Sejvar</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium</article-title>. <source>Clin Infect Dis</source> <volume>57</volume>: <fpage>1114</fpage>–<lpage>1128</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Spuesens1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spuesens</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Fraaij</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Visser</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Hoogenboezem</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hop</surname><given-names>WC</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Carriage of <italic>Mycoplasma pneumoniae</italic> in the upper respiratory tract of symptomatic and asymptomatic children: an observational study</article-title>. <source>PLoS Med</source> <volume>10</volume>: <fpage>e1001444</fpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Wood1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wood</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>VL</given-names></name>, <name name-style="western"><surname>Burks</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title><italic>Mycoplasma pneumoniae</italic> in children with acute and refractory asthma</article-title>. <source>Ann Allergy Asthma Immunol</source> <volume>110</volume>: <fpage>328</fpage>–<lpage>334.e1</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Jacobs1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jacobs</surname><given-names>E</given-names></name> (<year>1993</year>) <article-title>Serological diagnosis of <italic>Mycoplasma pneumoniae</italic> infections: a critical review of current procedures</article-title>. <source>Clin Infect Dis</source> <volume>17</volume> <supplement>Suppl 1</supplement><fpage>S79</fpage>–<lpage>S82</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Waites1"><label>16</label>
<mixed-citation publication-type="other" xlink:type="simple">Waites KB, Talkington DF (2004) <italic>Mycoplasma pneumoniae</italic> and its role as a human pathogen. Clin Microbiol Rev <volume>17</volume>: : 697–728, table of contents.</mixed-citation>
</ref>
<ref id="ppat.1003983-Loens1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Loens</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Goossens</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ieven</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Acute respiratory infection due to <italic>Mycoplasma pneumoniae</italic>: current status of diagnostic methods</article-title>. <source>Eur J Clin Microbiol Infect Dis</source> <volume>29</volume>: <fpage>1055</fpage>–<lpage>1069</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Nadal1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nadal</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bossart</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zucol</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Steiner</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Berger</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Community-acquired pneumonia in children due to <italic>Mycoplasma pneumoniae</italic>: diagnostic performance of a seminested 16S rDNA-PCR</article-title>. <source>Diagn Microbiol Infect Dis</source> <volume>39</volume>: <fpage>15</fpage>–<lpage>19</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Beersma1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beersma</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Dirven</surname><given-names>K</given-names></name>, <name name-style="western"><surname>van Dam</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Templeton</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Claas</surname><given-names>EC</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Evaluation of 12 commercial tests and the complement fixation test for <italic>Mycoplasma pneumoniae</italic>-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard"</article-title>. <source>J Clin Microbiol</source> <volume>43</volume>: <fpage>2277</fpage>–<lpage>2285</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Ozaki1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ozaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nishimura</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Watanabe</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Muto</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Utility of a rapid diagnosis kit for <italic>Mycoplasma pneumoniae</italic> pneumonia in children, and the antimicrobial susceptibility of the isolates</article-title>. <source>J Infect Chemother</source> <volume>13</volume>: <fpage>204</fpage>–<lpage>207</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Gavranich1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gavranich</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>AB</given-names></name> (<year>2005</year>) <article-title>Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to <italic>Mycoplasma pneumoniae</italic> in children</article-title>. <source>Cochrane Database Syst Rev</source> <volume>2005</volume>: <fpage>CD004875</fpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Reiber1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reiber</surname><given-names>H</given-names></name> (<year>1994</year>) <article-title>Flow rate of cerebrospinal fluid (CSF)— a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases</article-title>. <source>J Neurol Sci</source> <volume>122</volume>: <fpage>189</fpage>–<lpage>203</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Jacobs2"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jacobs</surname><given-names>E</given-names></name> (<year>2012</year>) <article-title><italic>Mycoplasma pneumoniae</italic>: now in the focus of clinicians and epidemiologists</article-title>. <source>Euro Surveill</source> <volume>17</volume>: <fpage>1</fpage>–<lpage>3</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Dumke1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dumke</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Strubel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cyncynatus</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Nuyttens</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Herrmann</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Optimized serodiagnosis of <italic>Mycoplasma pneumoniae</italic> infections</article-title>. <source>Diagn Microbiol Infect Dis</source> <volume>73</volume>: <fpage>200</fpage>–<lpage>203</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Daxboeck1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Daxboeck</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Blacky</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Seidl</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Krause</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Assadian</surname><given-names>O</given-names></name> (<year>2004</year>) <article-title>Diagnosis, treatment, and prognosis of <italic>Mycoplasma pneumoniae</italic> childhood encephalitis: systematic review of 58 cases</article-title>. <source>J Child Neurol</source> <volume>19</volume>: <fpage>865</fpage>–<lpage>871</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Domenech1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Domenech</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Leveque</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Lina</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Najioullah</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Floret</surname><given-names>D</given-names></name> (<year>2009</year>) <article-title>Role of <italic>Mycoplasma pneumoniae</italic> in pediatric encephalitis</article-title>. <source>Eur J Clin Microbiol Infect Dis</source> <volume>28</volume>: <fpage>91</fpage>–<lpage>94</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Narita3"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Narita</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yamada</surname><given-names>S</given-names></name> (<year>2001</year>) <article-title>Two distinct patterns of central nervous system complications due to <italic>Mycoplasma pneumoniae</italic> infection</article-title>. <source>Clin Infect Dis</source> <volume>33</volume>: <fpage>916</fpage>–<lpage>917</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Bencina1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bencina</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dovc</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mueller-Premru</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Avsic-Zupanc</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Socan</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Intrathecal synthesis of specific antibodies in patients with invasion of the central nervous system by <italic>Mycoplasma pneumoniae</italic></article-title>. <source>Eur J Clin Microbiol Infect Dis</source> <volume>19</volume>: <fpage>521</fpage>–<lpage>530</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-MeyerSauteur1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meyer Sauteur</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Relly</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hackenberg</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Stahr</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Berger</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title><italic>Mycoplasma pneumoniae</italic> Intrathecal Antibody Responses in Bickerstaff Brain Stem Encephalitis</article-title>. <source>Neuropediatrics</source> <volume>45</volume>: <fpage>61</fpage>–<lpage>63</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Christie2"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Christie</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Honarmand</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yagi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ruiz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Glaser</surname><given-names>CA</given-names></name> (<year>2007</year>) <article-title>Anti-galactocerebroside testing in <italic>Mycoplasma pneumoniae</italic>-associated encephalitis</article-title>. <source>J Neuroimmunol</source> <volume>189</volume>: <fpage>129</fpage>–<lpage>131</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Jacobs3"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jacobs</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bartl</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Oberle</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Schiltz</surname><given-names>E</given-names></name> (<year>1995</year>) <article-title>Molecular mimicry by <italic>Mycoplasma pneumoniae</italic> to evade the induction of adherence inhibiting antibodies</article-title>. <source>J Med Microbiol</source> <volume>43</volume>: <fpage>422</fpage>–<lpage>429</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Kusunoki1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kusunoki</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shiina</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kanazawa</surname><given-names>I</given-names></name> (<year>2001</year>) <article-title>Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry</article-title>. <source>Neurology</source> <volume>57</volume>: <fpage>736</fpage>–<lpage>738</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Rottem1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rottem</surname><given-names>S</given-names></name> (<year>2003</year>) <article-title>Interaction of mycoplasmas with host cells</article-title>. <source>Physiol Rev</source> <volume>83</volume>: <fpage>417</fpage>–<lpage>432</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Willison1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Willison</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Yuki</surname><given-names>N</given-names></name> (<year>2002</year>) <article-title>Peripheral neuropathies and anti-glycolipid antibodies</article-title>. <source>Brain</source> <volume>125</volume>: <fpage>2591</fpage>–<lpage>2625</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Ang1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ang</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Tio-Gillen</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Groen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Herbrink</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>BC</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Cross-reactive anti-galactocerebroside antibodies and <italic>Mycoplasma pneumoniae</italic> infections in Guillain-Barré syndrome</article-title>. <source>J Neuroimmunol</source> <volume>130</volume>: <fpage>179</fpage>–<lpage>183</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Susuki1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Susuki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Odaka</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mori</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hirata</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yuki</surname><given-names>N</given-names></name> (<year>2004</year>) <article-title>Acute motor axonal neuropathy after Mycoplasma infection: Evidence of molecular mimicry</article-title>. <source>Neurology</source> <volume>62</volume>: <fpage>949</fpage>–<lpage>956</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Arakawa1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arakawa</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yuhara</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Todokoro</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mochizuki</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Immunoadsorption therapy for a child with Guillain-Barré syndrome subsequent to Mycoplasma infection: a case study</article-title>. <source>Brain Dev</source> <volume>27</volume>: <fpage>431</fpage>–<lpage>433</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Samukawa1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Samukawa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hamada</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kuwahara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Takada</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hirano</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Clinical features in Guillain-Barré syndrome with anti-Gal-C antibody</article-title>. <source>J Neurol Sci</source> <volume>337</volume>: <fpage>55</fpage>–<lpage>60</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-vanDoorn1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Doorn</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Ruts</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>BC</given-names></name> (<year>2008</year>) <article-title>Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome</article-title>. <source>Lancet Neurol</source> <volume>7</volume>: <fpage>939</fpage>–<lpage>950</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Saida1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saida</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Saida</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Dorfman</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Silberberg</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Sumner</surname><given-names>AJ</given-names></name>, <etal>et al</etal>. (<year>1979</year>) <article-title>Experimental allergic neuritis induced by sensitization with galactocerebroside</article-title>. <source>Science</source> <volume>204</volume>: <fpage>1103</fpage>–<lpage>1106</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Nishimura1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nishimura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Saida</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kuroki</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kawabata</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Obayashi</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>Post-infectious encephalitis with anti-galactocerebroside antibody subsequent to <italic>Mycoplasma pneumoniae</italic> infection</article-title>. <source>J Neurol Sci</source> <volume>140</volume>: <fpage>91</fpage>–<lpage>95</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Kumada1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kumada</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kusaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Okaniwa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Kusunoki</surname><given-names>S</given-names></name> (<year>1997</year>) <article-title>Encephalomyelitis subsequent to mycoplasma infection with elevated serum anti-Gal C antibody</article-title>. <source>Pediatr Neurol</source> <volume>16</volume>: <fpage>241</fpage>–<lpage>244</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Sugeno1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sugeno</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kawaguchi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hasegawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kuroda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nakashima</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>A case with anti-galactocerebroside antibody-positive <italic>Mycoplasma pneumoniae</italic> meningoencephalitis presenting secondary hypersomnia</article-title>. <source>Neurol Sci</source> <volume>33</volume>: <fpage>1473</fpage>–<lpage>1476</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Kikuchi1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kikuchi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tagawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Iwamoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hoshino</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yuki</surname><given-names>N</given-names></name> (<year>1997</year>) <article-title>Bickerstaff's brainstem encephalitis associated with IgG anti-GQ1b antibody subsequent to <italic>Mycoplasma pneumoniae</italic> infection: favorable response to immunoadsorption therapy</article-title>. <source>J Child Neurol</source> <volume>12</volume>: <fpage>403</fpage>–<lpage>405</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Steer1"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Steer</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Starr</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kornberg</surname><given-names>AJ</given-names></name> (<year>2006</year>) <article-title>Bickerstaff brainstem encephalitis associated with <italic>Mycoplasma pneumoniae</italic> infection</article-title>. <source>J Child Neurol</source> <volume>21</volume>: <fpage>533</fpage>–<lpage>534</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Fusco1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fusco</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bonini</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Soncini</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Frattini</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Giovannini</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Transient basal ganglia and thalamic involvement following <italic>Mycoplasma pneumoniae</italic> infection associated with antiganglioside antibodies</article-title>. <source>J Child Neurol</source> <volume>25</volume>: <fpage>1029</fpage>–<lpage>1033</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Odaka1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Odaka</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yuki</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yamada</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Koga</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Takemi</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome</article-title>. <source>Brain</source> <volume>126</volume>: <fpage>2279</fpage>–<lpage>2290</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Monteyne1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Monteyne</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Weissbrich</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zardini</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ciardi</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>The detection of intrathecal synthesis of anti-herpes simplex IgG antibodies: comparison between an antigen-mediated immunoblotting technique and antibody index calculations. European Union Concerted Action on Virus Meningitis and Encephalitis</article-title>. <source>J Med Virol</source> <volume>53</volume>: <fpage>324</fpage>–<lpage>331</lpage>.</mixed-citation>
</ref>
<ref id="ppat.1003983-Granerod1"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Granerod</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zuckerman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mutton</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Davies</surname><given-names>NW</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Causality in acute encephalitis: defining aetiologies</article-title>. <source>Epidemiol Infect</source> <volume>138</volume>: <fpage>783</fpage>–<lpage>800</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>